457 related articles for article (PubMed ID: 9669389)
1. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
[TBL] [Abstract][Full Text] [Related]
2. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
Vuillez JP; Moro D; Brichon PY; Rouvier E; Brambilla E; Barbet J; Peltier P; Meyer P; Sarrazin R; Brambilla C
J Nucl Med; 1997 Apr; 38(4):507-11. PubMed ID: 9098191
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
Peltier P; Curtet C; Chatal JF; Le Doussal JM; Daniel G; Aillet G; Gruaz-Guyon A; Barbet J; Delaage M
J Nucl Med; 1993 Aug; 34(8):1267-73. PubMed ID: 8326383
[TBL] [Abstract][Full Text] [Related]
5. Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery.
de Labriolle-Vaylet C; Cattan P; Sarfati E; Wioland M; Billotey C; Brochériou C; Rouvier E; de Roquancourt A; Rostène W; Askienazy S; Barbet J; Milhaud G; Gruaz-Guyon A
Clin Cancer Res; 2000 Feb; 6(2):363-71. PubMed ID: 10690512
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer.
Bardiès M; Bardet S; Faivre-Chauvet A; Peltier P; Douillard JY; Mahé M; Fiche M; Lisbona A; Giacalone F; Meyer P; Gautherot E; Rouvier E; Barbet J; Chatal JF
J Nucl Med; 1996 Nov; 37(11):1853-9. PubMed ID: 8917192
[TBL] [Abstract][Full Text] [Related]
7. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody.
Aarts F; Boerman OC; Sharkey RM; Hendriks T; Chang CH; McBride WJ; Bleichrodt RP; Oyen WJ; Goldenberg DM
Cancer; 2010 Feb; 116(4 Suppl):1111-7. PubMed ID: 20127959
[TBL] [Abstract][Full Text] [Related]
8. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma.
Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771
[TBL] [Abstract][Full Text] [Related]
9. Intraoperative gamma probe detection of neuroendocrine tumors.
Adams S; Baum RP; Hertel A; Wenisch HJ; Staib-Sebler E; Herrmann G; Encke A; Hör G
J Nucl Med; 1998 Jul; 39(7):1155-60. PubMed ID: 9669386
[TBL] [Abstract][Full Text] [Related]
10. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
[TBL] [Abstract][Full Text] [Related]
11. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
12. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
[TBL] [Abstract][Full Text] [Related]
13. Pretargetted imaging of colorectal cancer recurrences using an 111In-labelled bivalent hapten and a bispecific antibody conjugate.
Chetanneau A; Barbet J; Peltier P; Le Doussal JM; Gruaz-Guyon A; Bernard AM; Resche I; Rouvier E; Bourguet P; Delaage M
Nucl Med Commun; 1994 Dec; 15(12):972-80. PubMed ID: 7715897
[TBL] [Abstract][Full Text] [Related]
14. Immunoscintigraphy using 111In-labeled F(ab')2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma.
Vuillez JP; Peltier P; Caravel JP; Chetanneau A; Saccavini JC; Chatal JF
J Clin Endocrinol Metab; 1992 Jan; 74(1):157-63. PubMed ID: 1727816
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
[TBL] [Abstract][Full Text] [Related]
16. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma.
Kurtaran A; Scheuba C; Kaserer K; Schima W; Czerny C; Angelberger P; Niederle B; Virgolini I
J Nucl Med; 1998 Nov; 39(11):1907-9. PubMed ID: 9829581
[TBL] [Abstract][Full Text] [Related]
17. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
18. Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma.
Magnani P; Paganelli G; Songini C; Samuel A; Sudati F; Siccardi AG; Fazio F
Br J Cancer; 1996 Sep; 74(5):825-31. PubMed ID: 8795589
[TBL] [Abstract][Full Text] [Related]
19. Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens. Results and clinical perspectives.
Rouvier E; Gautherot E; Meyer P; Barbet J
Horm Res; 1997; 47(4-6):163-7. PubMed ID: 9167948
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
